MCID: FBR086
MIFTS: 50

Fibrolamellar Carcinoma

Categories: Rare diseases, Cancer diseases, Liver diseases

Aliases & Classifications for Fibrolamellar Carcinoma

MalaCards integrated aliases for Fibrolamellar Carcinoma:

Name: Fibrolamellar Carcinoma 12 49
Fibrolamellar Hepatocellular Carcinoma 12 49 55 41 69
Eosinophilic Hepatocellular Carcinoma with Lamellar Fibrosis 49
Polygonal Cell Hepatocellular Carcinoma with Fibrous Stroma 49
Hepatocellular Carcinoma with Increased Stromal Fibrosis 49
Hepatocellular Carcinoma, Fibrolamellar 12
Hepatocellular Fibrolamellar Carcinoma 14
Eosinophilic Glassy Cell Hepatoma 49
Fibrolamellar Oncocytic Hepatoma 49
Oncocytic Hepatocellular Tumor 12
Fibrolamellar Hepatocarcinoma 55
Fl-Hcc 49
Fhcc 55

Characteristics:

Orphanet epidemiological data:

55
fibrolamellar hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adolescent,Adult;

Classifications:

Orphanet: 55  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:5015
MeSH 41 C537258
NCIt 46 C4131
SNOMED-CT 64 15619004 253018005
Orphanet 55 ORPHA401920
UMLS via Orphanet 70 C0334287
ICD10 via Orphanet 33 C22.0
UMLS 69 C0334287

Summaries for Fibrolamellar Carcinoma

NIH Rare Diseases : 49 Fibrolamellar carcinoma (FLC) is a rare form of liver cancer which is generally diagnosed in adolescents and young adults (before age 40). Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified. FLC is typically treated with surgical resection. Last updated: 4/23/2015

MalaCards based summary : Fibrolamellar Carcinoma, also known as fibrolamellar hepatocellular carcinoma, is related to mixed fibrolamellar hepatocellular carcinoma and proliferating trichilemmal cyst, and has symptoms including malaise, icterus and fever. An important gene associated with Fibrolamellar Carcinoma is PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha), and among its related pathways/superpathways are Sertoli-Sertoli Cell Junction Dynamics and MAPK-Erk Pathway. The drugs Everolimus and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and bone marrow, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A hepatocellular carcinoma characterized microscopically by laminated fibrous layers interspersed between the tumour cells. The polygonal, deeply eosinophilic tumor cells arise in non-cirrhotic livers.

Wikipedia : 72 Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that... more...

Related Diseases for Fibrolamellar Carcinoma

Diseases related to Fibrolamellar Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 mixed fibrolamellar hepatocellular carcinoma 32.2 DNAJB1 PRKACA
2 proliferating trichilemmal cyst 10.5 KRT7 KRT8
3 endolymphatic sac tumor 10.5 KRT7 KRT8
4 cutaneous adenocystic carcinoma 10.5 KRT7 KRT8
5 hidrocystoma 10.5 KRT7 KRT8
6 prostate squamous cell carcinoma 10.5 KRT7 KRT8
7 apocrine sweat gland neoplasm 10.5 KRT7 KRT8
8 ovarian large-cell neuroendocrine carcinoma 10.5 KRT7 SYP
9 mucinous adenofibroma 10.5 KRT7 SYP
10 sensory organ benign neoplasm 10.5 KRT7 SYP
11 nasal cavity cancer 10.5 KRT7 KRT8
12 middle ear adenoma 10.5 KRT7 SYP
13 small cell carcinoma of the bladder 10.5 KRT7 SYP
14 brooke-spiegler syndrome 10.4 KRT7 KRT8
15 pancreatic serous cystadenoma 10.4 KRT7 SYP
16 pleomorphic carcinoma 10.4 KRT7 KRT8
17 mucinous ovarian cystadenoma 10.4 KRT7 SYP
18 glycogen-rich clear cell breast carcinoma 10.4 KRT7 SYP
19 pulmonary sclerosing hemangioma 10.4 KRT7 SYP
20 mucinous tubular and spindle renal cell carcinoma 10.4 KRT7 KRT8
21 seminal vesicle tumor 10.4 KRT7 SYP
22 lymphoepithelioma-like carcinoma 10.4 KRT7 KRT8
23 parachordoma 10.4 KRT7 VIM
24 adenoid squamous cell carcinoma 10.4 KRT7 VIM
25 nasal cavity squamous cell carcinoma 10.4 KRT7 KRT8
26 malignant mixed mullerian tumor 10.4 KRT7 VIM
27 nodular hidradenoma 10.4 KRT7 VIM
28 papillary adenoma 10.4 KRT7 VIM
29 eccrine porocarcinoma 10.4 KRT7 VIM
30 benign metastasizing leiomyoma 10.4 KRT7 VIM
31 monophasic synovial sarcoma 10.4 KRT7 VIM
32 sclerosing hemangioma 10.4 KRT7 SYP
33 mixed cell type cancer 10.4 KRT7 SYP
34 cervical clear cell adenocarcinoma 10.4 KRT8 SYP
35 papillary ependymoma 10.4 KRT8 SYP
36 metanephric adenoma 10.4 KRT7 VIM
37 breast secretory carcinoma 10.4 KRT7 KRT8
38 adenomatoid tumor 10.4 KRT7 VIM
39 ovarian mucinous neoplasm 10.4 KRT7 SYP
40 hidradenoma 10.4 KRT7 VIM
41 horseshoe kidney 10.3 KRT7 SYP
42 cystic teratoma 10.3 KRT7 SYP
43 primary hepatic neuroendocrine carcinoma 10.3 SYP VIM
44 mucinous cystadenocarcinoma 10.3 KRT7 VIM
45 papillary tumor of the pineal region 10.3 SYP VIM
46 spindle cell sarcoma 10.3 KRT7 VIM
47 rhabdoid meningioma 10.3 SYP VIM
48 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 10.3 KRT8 VIM
49 chordoid meningioma 10.3 SYP VIM
50 duodenum cancer 10.3 KRT7 SYP

Graphical network of the top 20 diseases related to Fibrolamellar Carcinoma:



Diseases related to Fibrolamellar Carcinoma

Symptoms & Phenotypes for Fibrolamellar Carcinoma

UMLS symptoms related to Fibrolamellar Carcinoma:


malaise, icterus, fever, abdominal pain

MGI Mouse Phenotypes related to Fibrolamellar Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 KRT8 PRKACA VIM CCKBR ITGA1 ITGAV
2 homeostasis/metabolism MP:0005376 9.61 KRT7 KRT8 NR0B2 PRKACA VIM CCKBR
3 renal/urinary system MP:0005367 9.1 PRKACA CCKBR ITGA1 ITGAV ITGB4 KRT7

Drugs & Therapeutics for Fibrolamellar Carcinoma

Drugs for Fibrolamellar Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2 159351-69-6 6442177
2
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
3
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181 3911
4
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
6
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
7
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
8
Lenograstim Approved, Investigational Phase 2 135968-09-1
9
Mesna Approved, Investigational Phase 2 3375-50-6 598
10
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
11
Mycophenolic acid Approved Phase 2 24280-93-1 446541
12
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
13
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
14
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
15 Anti-Bacterial Agents Phase 2
16 Antibiotics, Antitubercular Phase 2
17 Antifungal Agents Phase 2
18 Anti-Infective Agents Phase 2
19 Antineoplastic Agents, Hormonal Phase 2
20 Aromatase Inhibitors Phase 2
21 Estrogen Antagonists Phase 2
22 Estrogens Phase 2
23 Fertility Agents Phase 2
24 Hormone Antagonists Phase 2
25 Hormones Phase 2
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
27 Immunosuppressive Agents Phase 2
28 Steroid Synthesis Inhibitors Phase 2
29 Adjuvants, Immunologic Phase 2
30 Alkylating Agents Phase 2
31 Anti-Inflammatory Agents Phase 2
32 Antilymphocyte Serum Phase 2
33 Antimetabolites Phase 2
34 Antimetabolites, Antineoplastic Phase 2
35 Antirheumatic Agents Phase 2
36 Antitubercular Agents Phase 2
37 Calcineurin Inhibitors Phase 2
38 glucocorticoids Phase 2
39 Hematinics Phase 2
40 Liver Extracts Phase 2
41 Protective Agents Phase 2
42 Angiogenesis Inhibitors Phase 2
43 Angiogenesis Modulating Agents Phase 2
44 Endothelial Growth Factors Phase 1
45 Mitogens Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma Active, not recruiting NCT02234986 Phase 2 ENMD-2076
2 Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Active, not recruiting NCT01642186 Phase 2 everolimus;letrozole plus leuprolide;combination of everolimus, letrozole and leuprolide
3 Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) Active, not recruiting NCT02702960 Phase 2 Cyclophosphamide;Mesna;Filgrastim;Tacrolimus;mycophenolate mofetil;Prednisone;Antithymocyte globulin;fludarabine
4 Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma Terminated NCT01215565 Phase 2 Sutent
5 Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02159989 Phase 1 Sapanisertib
6 Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer Withdrawn NCT00899002

Search NIH Clinical Center for Fibrolamellar Carcinoma

Cochrane evidence based reviews: fibrolamellar hepatocellular carcinoma

Genetic Tests for Fibrolamellar Carcinoma

Anatomical Context for Fibrolamellar Carcinoma

MalaCards organs/tissues related to Fibrolamellar Carcinoma:

38
Liver, Endothelial, Bone Marrow, Bone, Testes

Publications for Fibrolamellar Carcinoma

Articles related to Fibrolamellar Carcinoma:

(show all 38)
# Title Authors Year
1
Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. ( 28862261 )
2017
2
Environmental exposures as a risk factor for fibrolamellar carcinoma. ( 28256571 )
2017
3
Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings. ( 28110996 )
2017
4
Fibrolamellar Carcinoma in the Carney Complex: PRKAR1A Loss Instead of the Classic DNAJB1-PRKACA Fusion. ( 29222914 )
2017
5
Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. ( 28304380 )
2017
6
Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. ( 27456016 )
2016
7
Duodenal Recurrence of Fibrolamellar Carcinoma 12 Years After Partial Hepatectomy and Adjuvant Chemotherapy. ( 27921059 )
2016
8
The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas. ( 26505878 )
2016
9
FGFR1 and FGFR2 in fibrolamellar carcinoma. ( 26259677 )
2015
10
Liver cancer: A model of fibrolamellar carcinoma. ( 26503883 )
2015
11
Caroli's Syndrome with Incidental Fibrolamellar Carcinoma on Liver Explant. ( 25990596 )
2015
12
Fibrolamellar carcinoma versus scirrhous hepatocellular carcinomaa88: diagnostic usefulness of CD68. ( 26712049 )
2015
13
DNAJB1-PRKACA is specific for fibrolamellar carcinoma. ( 25698061 )
2015
14
Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. ( 24844420 )
2014
15
CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients. ( 24896196 )
2014
16
Fibrolamellar carcinoma in a 62 year-old patient with human immunodeficiency virus infection. ( 24908574 )
2014
17
Combined hepatocellular carcinoma and fibrolamellar carcinoma presenting as two adjacent separate lesions in a young boy: first case report from Asia. ( 25374712 )
2013
18
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. ( 23505572 )
2013
19
Cytologic features of fibrolamellar carcinoma with mucin production: A rare variant of combined hepatocellular-cholangiocarcinoma. ( 23008149 )
2012
20
Loss of the orphan nuclear receptor SHP is more pronounced in fibrolamellar carcinoma than in typical hepatocellular carcinoma. ( 22292081 )
2012
21
Fibrolamellar carcinoma: 2012 update. ( 24278737 )
2012
22
Fibrolamellar carcinomas are positive for CD68. ( 21113139 )
2011
23
Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. ( 21344351 )
2011
24
Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. ( 21060828 )
2010
25
Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. ( 20495535 )
2010
26
[Fibrolamellar carcinoma of the liver]. ( 19507574 )
2009
27
Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. ( 18973922 )
2009
28
Fibrolamellar carcinoma presenting as a pancreatic mass: case report and review of the literature. ( 19415023 )
2009
29
Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. ( 18264082 )
2008
30
Shoulder pain as the first sign of a hepatic fibrolamellar carcinoma in a young man. ( 18568150 )
2008
31
Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. ( 17367606 )
2007
32
Review of the clinicopathologic features of fibrolamellar carcinoma. ( 17452818 )
2007
33
Electronic clinical challenges and images in GI. Fibrolamellar carcinoma. ( 17983790 )
2007
34
Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report. ( 16049296 )
2005
35
Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. ( 10190738 )
1999
36
Fibrolamellar carcinoma of the liver: composition of the extracellular matrix and expression of cell-matrix and cell-cell adhesion molecules. ( 8903387 )
1996
37
Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma. ( 7944660 )
1994
38
Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. ( 1699871 )
1990

Variations for Fibrolamellar Carcinoma

Cosmic variations for Fibrolamellar Carcinoma:

9 (show top 50) (show all 702)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43898 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.485T>G p.I162S 28
2 COSM10659 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.817C>T p.R273C 28
3 COSM43785 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.795G>A p.L265L 28
4 COSM10883 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.731G>A p.G244D 28
5 COSM11542 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.703A>G p.N235D 28
6 COSM45047 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.515T>G p.V172G 28
7 COSM10733 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.574C>T p.Q192* 28
8 COSM43737 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.830G>A p.C277Y 28
9 COSM43778 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.713G>T p.C238F 28
10 COSM43985 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.439G>A p.V147I 28
11 COSM44227 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.854A>T p.E285V 28
12 COSM10662 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.743G>A p.R248Q 28
13 COSM10801 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.404G>A p.C135Y 28
14 COSM44571 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.581T>G p.L194R 28
15 COSM11205 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.796G>C p.G266R 28
16 COSM44808 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.503A>C p.H168P 28
17 COSM44510 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.717C>G p.N239K 28
18 COSM11183 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.799C>T p.R267W 28
19 COSM43635 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.536A>T p.H179L 28
20 COSM10893 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.824G>A p.C275Y 28
21 COSM44129 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.729G>A p.M243I 28
22 COSM43850 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.659A>C p.Y220S 28
23 COSM10756 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.827C>T p.A276V 28
24 COSM43846 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.487T>C p.Y163H 28
25 COSM10725 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.701A>G p.Y234C 28
26 COSM10757 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.738G>C p.M246I 28
27 COSM43687 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.641A>G p.H214R 28
28 COSM44623 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.487T>A p.Y163N 28
29 COSM6815 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.461G>T p.G154V 28
30 COSM10656 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.742C>T p.R248W 28
31 COSM10714 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.473G>T p.R158L 28
32 COSM43791 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.994-2A>T p.? 28
33 COSM1651731 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.957G>A p.K319K 28
34 COSM44935 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.724T>A p.C242S 28
35 COSM10722 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.853G>A p.E285K 28
36 COSM10779 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.818G>T p.R273L 28
37 COSM44321 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.712T>C p.C238R 28
38 COSM43967 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.751A>T p.I251F 28
39 COSM44469 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.812A>T p.E271V 28
40 COSM10727 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.438G>A p.W146* 28
41 COSM43836 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.475G>C p.A159P 28
42 COSM11508 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.497C>A p.S166* 28
43 COSM43931 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.523C>A p.R175S 28
44 COSM10810 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.725G>T p.C242F 28
45 COSM10663 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.916C>T p.R306* 28
46 COSM44877 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.584T>A p.I195N 28
47 COSM11148 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.476C>T p.A159V 28
48 COSM44535 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.761T>A p.I254N 28
49 COSM45748 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.438G>T p.W146C 28
50 COSM10645 TP53 liver,NS,carcinoma,hepatocellular carcinoma c.527G>T p.C176F 28

Expression for Fibrolamellar Carcinoma

Search GEO for disease gene expression data for Fibrolamellar Carcinoma.

Pathways for Fibrolamellar Carcinoma

Pathways related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 ITGA1 ITGAV ITGB4 PRKACA
2
Show member pathways
12.53 ITGA1 ITGAV ITGB4 PRKACA
3
Show member pathways
12.51 ITGA1 ITGAV ITGB4 PRKACA
4 12.16 ITGAV KRT7 KRT8 VIM
5
Show member pathways
12.08 ITGA1 ITGAV ITGB4
6
Show member pathways
11.9 ITGA1 ITGAV ITGB4 PRKACA
7
Show member pathways
11.83 ITGA1 ITGAV ITGB4
8
Show member pathways
11.76 ITGA1 ITGAV ITGB4
9
Show member pathways
11.69 ITGA1 ITGAV ITGB4 PRKACA
10 11.64 ITGA1 ITGAV ITGB4
11
Show member pathways
11.61 KRT7 KRT8 VIM
12 11.43 ITGA1 ITGAV ITGB4
13 10.94 ITGA1 ITGAV ITGB4 PRKACA
14 10.79 ITGAV ITGB4 KRT8 VIM
15 10.74 ITGA1 ITGAV ITGB4 VIM
16 10.73 ITGA1 ITGAV ITGB4

GO Terms for Fibrolamellar Carcinoma

Cellular components related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.56 DNAJB1 ITGA1 ITGAV ITGB4 KRT7 KRT8
2 intermediate filament GO:0005882 9.33 KRT7 KRT8 VIM
3 integrin complex GO:0008305 8.8 ITGA1 ITGAV ITGB4

Biological processes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.46 ITGAV KRT7 KRT8 VIM
2 extracellular matrix organization GO:0030198 9.43 ITGA1 ITGAV ITGB4
3 digestive tract development GO:0048565 9.32 CCKBR ITGB4
4 cell-matrix adhesion GO:0007160 9.13 ITGA1 ITGAV ITGB4
5 integrin-mediated signaling pathway GO:0007229 8.8 ITGA1 ITGAV ITGB4

Molecular functions related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.33 KRT7 KRT8 VIM
2 insulin-like growth factor I binding GO:0031994 8.96 ITGAV ITGB4
3 neuregulin binding GO:0038132 8.62 ITGAV ITGB4

Sources for Fibrolamellar Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....